Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050 | 10% owner | December 13, 2019 | December 16, 2019 |
| Cogent Biosciences, Inc.UMRX · Entity 3793 | 10% owner | August 14, 2020 | August 18, 2020 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | 10% owner | February 10, 2025 | February 27, 2025 |
| Shockwave Medical, Inc.SWAV · Entity 90374 | 10% owner | March 11, 2019 | March 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONSTELLATION PHARMACEUTICALS INC
Report date December 13, 2019 · Filed December 16, 2019
Jointly reported with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management II, LLC, Shah Nimish P
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 4,016,873 |
Reported balance
After 2019-12-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-12-13 · Purchase · Acquired 400,000 · Balance 4,016,873 F1: Consists of an aggregate of 363,640 shares of Common Stock purchased by Venrock Healthcare Capital Partners III, L.P. ("VHCP III") and 36,360 shares of Common Stock purchased by VHCP Co-Investment Holdings III, LLC ("Co-Invest III") (collectively, the "VHCP III Funds"). F2: Consists of an aggregate of 2,287,598 shares of Common Stock held by VHCP III, 228,644 shares of Common Stock held by Co-Invest III, 1,067,801 shares of Common Stock held by Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and 432,830 shares of Common Stock held by VHCP Co-Investment Holdings II, LLC ("Co-Invest II" and collectively with VHCP II and the VHCP III Funds, the "VHCP Funds"). F3: VHCP Management III, LLC ("VHCPM III") is the sole general partner and the sole manager of VHCP III and Co-Invest III, respectively, and may be deemed to own the shares held by VHCP III and Co-Invest III. VHCP Management II, LLC ("VHCPM II") is the sole general partner and the sole manager of VHCP II and Co-Invest II, respectively, and may be deemed to own the shares held by VHCP II and Co-Invest II. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Drs. Koh and Shah, VHCPM II and VHCPM III disclaim beneficial ownership over all shares held by the VHCP Funds except to the extent of their indirect proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an aggregate of 363,640 shares of Common Stock purchased by Venrock Healthcare Capital Partners III, L.P. ("VHCP III") and 36,360 shares of Common Stock purchased by VHCP Co-Investment Holdings III, LLC ("Co-Invest III") (collectively, the "VHCP III Funds").
F2: Consists of an aggregate of 2,287,598 shares of Common Stock held by VHCP III, 228,644 shares of Common Stock held by Co-Invest III, 1,067,801 shares of Common Stock held by Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and 432,830 shares of Common Stock held by VHCP Co-Investment Holdings II, LLC ("Co-Invest II" and collectively with VHCP II and the VHCP III Funds, the "VHCP Funds").
F3: VHCP Management III, LLC ("VHCPM III") is the sole general partner and the sole manager of VHCP III and Co-Invest III, respectively, and may be deemed to own the shares held by VHCP III and Co-Invest III. VHCP Management II, LLC ("VHCPM II") is the sole general partner and the sole manager of VHCP II and Co-Invest II, respectively, and may be deemed to own the shares held by VHCP II and Co-Invest II. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Drs. Koh and Shah, VHCPM II and VHCPM III disclaim beneficial ownership over all shares held by the VHCP Funds except to the extent of their indirect proportionate pecuniary interest therein.
Cogent Biosciences, Inc.
Report date August 14, 2020 · Filed August 18, 2020
Jointly reported with Venrock Healthcare Capital Partners III, L.P., Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Shah Nimish P
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy funds | 4,004,273 |
Reported balance
After 2020-08-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-08-14 · Purchase · Acquired 100,000 · Balance 4,004,273 F1: Consists of (i) 26,430 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 10,710 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 57,150 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 5,710 shares purchased by VHCP Co-Investment Holdings III, LLC. F2: Consists of (i) 1,058,331 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 428,853 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,288,445 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 228,644 shares owned by VHCP Co-Investment Holdings III, LLC. F3: VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Associates II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the voting members of VHCPM2 and VHCPM3. Each of VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares, but each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectBy funds | 4,254,273 |
Reported balance
After 2020-08-17 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-08-17 · Purchase · Acquired 250,000 · Balance 4,254,273 F4: Consists of (i) 66,075 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 26,775 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 142,875 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 14,275 shares purchased by VHCP Co-Investment Holdings III, LLC. F3: VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Associates II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the voting members of VHCPM2 and VHCPM3. Each of VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares, but each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their respective pecuniary interests therein. F5: Consists of (i) 1,124,406 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 455,628 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,431,320 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 242,919 shares owned by VHCP Co-Investment Holdings III, LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy funds | 4,355,273 |
Reported balance
After 2020-08-18 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-08-18 · Purchase · Acquired 101,000 · Balance 4,355,273 F6: Consists of (i) 26,694 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 10,817 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 57,722 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 5,767 shares purchased by VHCP Co-Investment Holdings III, LLC. F3: VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Associates II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the voting members of VHCPM2 and VHCPM3. Each of VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares, but each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their respective pecuniary interests therein. F7: Consists of (i) 1,151,100 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 466,445 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,489,042 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 248,686 shares owned by VHCP Co-Investment Holdings III, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of (i) 26,430 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 10,710 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 57,150 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 5,710 shares purchased by VHCP Co-Investment Holdings III, LLC.
F2: Consists of (i) 1,058,331 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 428,853 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,288,445 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 228,644 shares owned by VHCP Co-Investment Holdings III, LLC.
F3: VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Associates II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the voting members of VHCPM2 and VHCPM3. Each of VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares, but each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their respective pecuniary interests therein.
F4: Consists of (i) 66,075 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 26,775 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 142,875 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 14,275 shares purchased by VHCP Co-Investment Holdings III, LLC.
F5: Consists of (i) 1,124,406 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 455,628 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,431,320 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 242,919 shares owned by VHCP Co-Investment Holdings III, LLC.
F6: Consists of (i) 26,694 shares purchased by Venrock Healthcare Capital Partners II, LP; (ii) 10,817 shares purchased by VHCP Co-Investment Holdings II, LLC; (iii) 57,722 shares purchased by Venrock Healthcare Capital Partners III, LP; and (iv) 5,767 shares purchased by VHCP Co-Investment Holdings III, LLC.
F7: Consists of (i) 1,151,100 shares owned by Venrock Healthcare Capital Partners II, LP; (ii) 466,445 shares owned by VHCP Co-Investment Holdings II, LLC; (iii) 2,489,042 shares owned by Venrock Healthcare Capital Partners III, LP; and (iv) 248,686 shares owned by VHCP Co-Investment Holdings III, LLC.
Oruka Therapeutics, Inc.
Report date February 10, 2025 · Filed February 27, 2025
Jointly reported with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Shah Nimish P
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 4,026,120 |
Reported balance
After 2025-02-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-02-10 · Purchase · Acquired 574 · Balance 4,026,120 F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.88 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F2: Consists of (i) 835,614 shares held by VHCP3; (ii) 83,701 shares held by VHCP Co-3; and (iii) 3,106,805 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 4,035,713 |
Reported balance
After 2025-02-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-02-11 · Purchase · Acquired 9,593 · Balance 4,035,713 F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.86 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F5: Consists of (i) 837,271 shares held by VHCP3; (ii) 83,867 shares held by VHCP Co-3; and (iii) 3,114,575 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 4,044,684 |
Reported balance
After 2025-02-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-02-12 · Purchase · Acquired 8,971 · Balance 4,044,684 F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.25 to $12.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F7: Consists of (i) 838,821 shares held by VHCP3; (ii) 84,022 shares held by VHCP Co-3; and (iii) 3,121,841 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 4,059,634 |
Reported balance
After 2025-02-13 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-02-13 · Purchase · Acquired 14,950 · Balance 4,059,634 F8: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F9: Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 4,148,428 |
Reported balance
After 2025-02-14 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2025-02-14 · Purchase · Acquired 88,794 · Balance 4,148,428 F10: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.17 to $11.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. F11: Consists of (i) 856,747 shares held by VHCP3; (ii) 85,816 shares held by VHCP Co-3; and (iii) 3,205,865 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.88 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F2: Consists of (i) 835,614 shares held by VHCP3; (ii) 83,701 shares held by VHCP Co-3; and (iii) 3,106,805 shares held by VHCP EG.
F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
F4: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.86 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F5: Consists of (i) 837,271 shares held by VHCP3; (ii) 83,867 shares held by VHCP Co-3; and (iii) 3,114,575 shares held by VHCP EG.
F6: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.25 to $12.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F7: Consists of (i) 838,821 shares held by VHCP3; (ii) 84,022 shares held by VHCP Co-3; and (iii) 3,121,841 shares held by VHCP EG.
F8: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F9: Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG.
F10: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.17 to $11.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
F11: Consists of (i) 856,747 shares held by VHCP3; (ii) 85,816 shares held by VHCP Co-3; and (iii) 3,205,865 shares held by VHCP EG.
Shockwave Medical, Inc.
Report date March 11, 2019 · Filed March 13, 2019
Jointly reported with Venrock Associates VII, L.P., Venrock Healthcare Capital Partners II, L.P., Venrock Partners VII, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Management VII, LLC, Shah Nimish P, VHCP Management II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 2,122,021 |
Last balance in matching sequence
After 2019-03-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-03-11 · Conversion · Acquired 1,105,529 · Balance 1,105,529 F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Row 2 · 2019-03-11 · Conversion · Acquired 1,016,492 · Balance 2,122,021 F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Funds | 0 |
Reported balance
After 2019-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-11 · Conversion · Acquired 1,105,529 · Balance 0 F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F2: Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Funds | 0 |
Reported balance
After 2019-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-11 · Conversion · Acquired 1,016,492 · Balance 0 F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F3: Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.
F2: Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC.
F3: Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC.
F4: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Altimmune, Inc.
Report date February 25, 2021 · Filed March 01, 2021
Jointly reported with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management II, LLC, Shah Nimish P
Section 16 reporting ended · disclosed 2021-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 3,500,000 |
Reported balance
After 2021-02-25 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-02-25 · Other · Disposed 1,000,000 · Balance 3,500,000 F1: On February 25, 2021, the Issuer entered into an exchange agreement with the Reporting Persons pursuant to which the Issuer exchanged an aggregate of 1,000,000 shares of common stock owned by the Reporting Persons for pre-funded warrants (the "Exchange Warrants") to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.0001 per share. F2: Consists of 925,050 shares held by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), 374,849 shares held by VHCP Co-Investment Holdings II, LLC ("VHCP II Co"), 2,000,252 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP III") and 199,849 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP III Co"). F3: VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II and VHCPM III. Dr. Koh, Mr. Shah, VHCPM II and VHCPM III disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III and VHCP III Co, except to the extent of their respective indirect pecuniary interests therein. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Funds | 1,000,000 |
Reported balance
After 2021-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-25 · Other · Acquired 1,000,000 · Balance 1,000,000 F1: On February 25, 2021, the Issuer entered into an exchange agreement with the Reporting Persons pursuant to which the Issuer exchanged an aggregate of 1,000,000 shares of common stock owned by the Reporting Persons for pre-funded warrants (the "Exchange Warrants") to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.0001 per share. F4: The Exchange Warrants are exercisable at any time, except that the Exchange Warrants will not be exercised by the Reporting Persons if, upon giving effect or immediately prior thereto, the Reporting Persons would beneficially own more than 9.99% of the total number of the Issuer's issued and outstanding common stock, which percentage may change at the holders' election to any other number less than or equal to 19.99% upon 61 days' notice to the Issuer. F5: The Exchange Warrants have no expiration date. F6: Consists of 264,300 shares underlying Exchange Warrants held by VHCP II, 107,100 shares underlying Exchange Warrants held by VHCP II Co, 571,500 shares underlying Exchange Warrants held by VHCP III and 57,100 shares underlying Exchange Warrants held by VHCP III Co. F3: VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II and VHCPM III. Dr. Koh, Mr. Shah, VHCPM II and VHCPM III disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III and VHCP III Co, except to the extent of their respective indirect pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 25, 2021, the Issuer entered into an exchange agreement with the Reporting Persons pursuant to which the Issuer exchanged an aggregate of 1,000,000 shares of common stock owned by the Reporting Persons for pre-funded warrants (the "Exchange Warrants") to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.0001 per share.
F2: Consists of 925,050 shares held by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), 374,849 shares held by VHCP Co-Investment Holdings II, LLC ("VHCP II Co"), 2,000,252 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP III") and 199,849 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP III Co").
F3: VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II and VHCPM III. Dr. Koh, Mr. Shah, VHCPM II and VHCPM III disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III and VHCP III Co, except to the extent of their respective indirect pecuniary interests therein.
F4: The Exchange Warrants are exercisable at any time, except that the Exchange Warrants will not be exercised by the Reporting Persons if, upon giving effect or immediately prior thereto, the Reporting Persons would beneficially own more than 9.99% of the total number of the Issuer's issued and outstanding common stock, which percentage may change at the holders' election to any other number less than or equal to 19.99% upon 61 days' notice to the Issuer.
F5: The Exchange Warrants have no expiration date.
F6: Consists of 264,300 shares underlying Exchange Warrants held by VHCP II, 107,100 shares underlying Exchange Warrants held by VHCP II Co, 571,500 shares underlying Exchange Warrants held by VHCP III and 57,100 shares underlying Exchange Warrants held by VHCP III Co.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Disposed 1,106 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 1,035,657 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: The Reporting Person, a member of the Board of Directors of the Issuer, is a member of VHCP Management II, LLC, the sole general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCPII") and the sole manager of VHCP Co-Investment Holdings II, LLC ("Co-Invest II") and, as such, may be deemed to beneficially own the securities owned by each of VHCPII and Co-Invest II. The Reporting Person disclaims beneficial ownership of the shares beneficially owned by VHCPII and Co-Invest II, except to the extent of his pecuniary interest therein. F4: Consists of (i) 736,871 shares held by VHCPII, and (ii) 298,786 shares held by Co-Invest II. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2026-02-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 26,496 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.25 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 2,454 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-15 · Disposition to issuer · Disposed 2,905 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: The Reporting Person, a member of the Board of Directors of the Issuer, is a member of VHCP Management II, LLC, the sole general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCPII") and the sole manager of VHCP Co-Investment Holdings II, LLC ("Co-Invest II") and, as such, may be deemed to beneficially own the securities owned by each of VHCPII and Co-Invest II. The Reporting Person disclaims beneficial ownership of the shares beneficially owned by VHCPII and Co-Invest II, except to the extent of his pecuniary interest therein.
F4: Consists of (i) 736,871 shares held by VHCPII, and (ii) 298,786 shares held by Co-Invest II.
F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Bellerophon Therapeutics, Inc.
Report date October 24, 2019 · Filed October 28, 2019
Jointly reported with VENROCK ASSOCIATES IV L P, VENROCK ENTREPRENEURS FUND IV L P, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, L.P., Venrock Management IV, LLC, Venrock Partners Management, LLC, Venrock Partners, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management II, LLC
Section 16 reporting ended · disclosed 2019-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy funds | 6,435,173 |
Last balance in matching sequence
After 2019-10-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2019-10-24 · Sale · Disposed 704,595 · Balance 6,824,425 F1: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F2: Consists of: 316,797 shares sold by Venrock Healthcare Capital Partners II, LP, 128,431 shares sold by VHCP Co-Investment Holdings II, LLC, 235,791 shares sold by Venrock Healthcare Capital Partners III, LP and 23,576 shares sold by VHCP Co-Investment Holdings III, LLC. F3: The price in Column 4 is a weighted average price. These shares were sold in multiple transactions a prices within a range of $1.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. F4: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Row 2 · 2019-10-25 · Sale · Disposed 56,242 · Balance 6,768,183 F1: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F5: Consists of: 25,287 shares sold by Venrock Healthcare Capital Partners II, LP, 10,252 shares sold by VHCP Co-Investment Holdings II, LLC, 18,821 shares sold by Venrock Healthcare Capital Partners III, LP and 1,882 shares sold by VHCP Co-Investment Holdings III, LLC. F3: The price in Column 4 is a weighted average price. These shares were sold in multiple transactions a prices within a range of $1.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. F4: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Row 3 · 2019-10-28 · Sale · Disposed 333,010 · Balance 6,435,173 F1: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F6: Consists of: 149,726 shares sold by Venrock Healthcare Capital Partners II, LP, 60,700 shares sold by VHCP Co-Investment Holdings II, LLC, 111,441 shares sold by Venrock Healthcare Capital Partners III, LP and 11,143 shares sold by VHCP Co-Investment Holdings III, LLC. F3: The price in Column 4 is a weighted average price. These shares were sold in multiple transactions a prices within a range of $1.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. F4: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons.
F2: Consists of: 316,797 shares sold by Venrock Healthcare Capital Partners II, LP, 128,431 shares sold by VHCP Co-Investment Holdings II, LLC, 235,791 shares sold by Venrock Healthcare Capital Partners III, LP and 23,576 shares sold by VHCP Co-Investment Holdings III, LLC.
F3: The price in Column 4 is a weighted average price. These shares were sold in multiple transactions a prices within a range of $1.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
F4: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein.
F5: Consists of: 25,287 shares sold by Venrock Healthcare Capital Partners II, LP, 10,252 shares sold by VHCP Co-Investment Holdings II, LLC, 18,821 shares sold by Venrock Healthcare Capital Partners III, LP and 1,882 shares sold by VHCP Co-Investment Holdings III, LLC.
F6: Consists of: 149,726 shares sold by Venrock Healthcare Capital Partners II, LP, 60,700 shares sold by VHCP Co-Investment Holdings II, LLC, 111,441 shares sold by Venrock Healthcare Capital Partners III, LP and 11,143 shares sold by VHCP Co-Investment Holdings III, LLC.
KalVista Pharmaceuticals, Inc.
Report date March 25, 2026 · Filed March 27, 2026
Jointly reported with Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management EG, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, Shah Nimish P
Section 16 reporting ended · disclosed 2026-03-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 5,129,500 |
Reported balance
After 2026-03-25 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-03-25 · Sale · Disposed 174,485 · Balance 5,129,500 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $16.51 to $17.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2: Consists of (i) 1,105,126 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,550 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,913,824 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 5,129,340 |
Reported balance
After 2026-03-25 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-03-25 · Sale · Disposed 160 · Balance 5,129,340 F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.51 to $17.55 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5: Consists of (i) 1,105,092 shares held by VHCP3; (ii) 110,547 shares held by VHCP Co-3; and (iii) 3,913,701 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 5,107,954 |
Reported balance
After 2026-03-26 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-03-26 · Sale · Disposed 21,386 · Balance 5,107,954 F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.07 to $18.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F7: Consists of (i) 1,100,485 shares held by VHCP3; (ii) 110,085 shares held by VHCP Co-3; and (iii) 3,897,384 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 5,092,537 |
Reported balance
After 2026-03-26 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-03-26 · Sale · Disposed 15,417 · Balance 5,092,537 F8: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.07 to $19.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F9: Consists of (i) 1,097,164 shares held by VHCP3; (ii) 109,752 shares held by VHCP Co-3; and (iii) 3,885,621 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 5,089,354 |
Reported balance
After 2026-03-26 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-03-26 · Sale · Disposed 3,183 · Balance 5,089,354 F10: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.07 to $19.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F11: Consists of (i) 1,096,478 shares held by VHCP3; (ii) 109,684 shares held by VHCP Co-3; and (iii) 3,883,192 shares held by VHCP EG. F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $16.51 to $17.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F2: Consists of (i) 1,105,126 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,550 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,913,824 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
F3: VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.51 to $17.55 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F5: Consists of (i) 1,105,092 shares held by VHCP3; (ii) 110,547 shares held by VHCP Co-3; and (iii) 3,913,701 shares held by VHCP EG.
F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.07 to $18.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F7: Consists of (i) 1,100,485 shares held by VHCP3; (ii) 110,085 shares held by VHCP Co-3; and (iii) 3,897,384 shares held by VHCP EG.
F8: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.07 to $19.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F9: Consists of (i) 1,097,164 shares held by VHCP3; (ii) 109,752 shares held by VHCP Co-3; and (iii) 3,885,621 shares held by VHCP EG.
F10: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.07 to $19.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F11: Consists of (i) 1,096,478 shares held by VHCP3; (ii) 109,684 shares held by VHCP Co-3; and (iii) 3,883,192 shares held by VHCP EG.
Tricida, Inc.
Report date October 24, 2022 · Filed October 26, 2022
Jointly reported with Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Shah Nimish P
Section 16 reporting ended · disclosed 2022-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 3,751,406 |
Last balance in matching sequence
After 2022-10-26 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-10-24 · Sale · Disposed 2,113,948 · Balance 8,088,998 F1: Consists of (i) 202,708 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), (ii) 82,148 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"), (iii) 617,948 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (iv) 61,806 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (v) 1,149,338 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.59 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Row 2 · 2022-10-25 · Sale · Disposed 1,970,418 · Balance 6,118,580 F4: The shares sold on October 25, 2022 consist of (i) 188,945 shares sold by VHCP II, (ii) 76,569 shares sold by VHCP Co-2, (iii) 575,992 shares sold by VHCP III, (iv) 57,610 shares sold by VHCP Co-3 and (v) 1,071,302 shares sold by VHCP EG. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. Row 3 · 2022-10-26 · Sale · Disposed 2,367,174 · Balance 3,751,406 F6: The shares sold on October 26, 2022 consist of (i) 226,991 shares sold by VHCP II, (ii) 91,988 shares sold by VHCP Co-2, (iii) 691,971 shares sold by VHCP III, (iv) 69,208 shares sold by VHCP Co-3 and (v) 1,287,016 shares sold by VHCP EG. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of (i) 202,708 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), (ii) 82,148 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"), (iii) 617,948 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (iv) 61,806 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (v) 1,149,338 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.59 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein.
F4: The shares sold on October 25, 2022 consist of (i) 188,945 shares sold by VHCP II, (ii) 76,569 shares sold by VHCP Co-2, (iii) 575,992 shares sold by VHCP III, (iv) 57,610 shares sold by VHCP Co-3 and (v) 1,071,302 shares sold by VHCP EG.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F6: The shares sold on October 26, 2022 consist of (i) 226,991 shares sold by VHCP II, (ii) 91,988 shares sold by VHCP Co-2, (iii) 691,971 shares sold by VHCP III, (iv) 69,208 shares sold by VHCP Co-3 and (v) 1,287,016 shares sold by VHCP EG.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Vistagen Therapeutics, Inc.
Report date July 12, 2022 · Filed July 14, 2022
Jointly reported with Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Shah Nimish P
Section 16 reporting ended · disclosed 2022-07-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 20,637,286 |
Reported balance
After 2022-07-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-07-12 · Sale · Disposed 60,000 · Balance 20,637,286 F1: Consists of 14,348 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), 5,814 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP II Co"), 4,688 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), 469 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP III Co") and 34,681 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: Consists of 4,935,020 shares held by VHCP II, 1,999,971 shares held by VHCP II Co, 1,612,582 shares held by VHCP III, 161,351 shares held by VHCP III Co and 11,928,362 shares held by VHCP EG. F4: VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC ("VHCPM EG") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II, VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM II, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III, VHCP III Co and VHCP EG, except to the extent of their respective indirect pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 14,348 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), 5,814 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP II Co"), 4,688 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), 469 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP III Co") and 34,681 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: Consists of 4,935,020 shares held by VHCP II, 1,999,971 shares held by VHCP II Co, 1,612,582 shares held by VHCP III, 161,351 shares held by VHCP III Co and 11,928,362 shares held by VHCP EG.
F4: VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC ("VHCPM EG") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II, VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM II, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III, VHCP III Co and VHCP EG, except to the extent of their respective indirect pecuniary interests therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2020 Filed May 28, 2020 18:34 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock | 27,763 | $7.79 | $216,273.77 |
DisclosureSEC source: 0001738048-20-000002 · edgar.xml · nonDerivative · entry 5 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 2,826,289 F10 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.61 to $8.60, inclusive. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Dr. Koh, Mr. Shah, VHCPM III and VHCPM II disclaim beneficial ownership over all shares held by VHCP III, VHCP III Co, VHCP II and VHCP II Co, except to the extent of their respective indirect pecuniary interests therein. F11 · ownership.nature: Represents (a) 1,615,227 shares of common stock held by VHCP III, (b) 161,380 shares of common stock held by VHCP III Co, (c) 746,988 shares of common stock held by VHCP II, and (d) 302,694 shares of common stock held by VHCP II Co. Read SEC document |
| May 27, 2020 Filed May 28, 2020 18:34 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock | 277,000 | $7.92 | $2,193,840.00 |
DisclosureSEC source: 0001738048-20-000002 · edgar.xml · nonDerivative · entry 4 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 2,798,526 F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.63 to $8.05, inclusive. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Dr. Koh, Mr. Shah, VHCPM III and VHCPM II disclaim beneficial ownership over all shares held by VHCP III, VHCP III Co, VHCP II and VHCP II Co, except to the extent of their respective indirect pecuniary interests therein. F9 · ownership.nature: Represents (a) 1,599,360 shares of common stock held by VHCP III, (b) 159,795 shares of common stock held by VHCP III Co, (c) 739,650 shares of common stock held by VHCP II, and (d) 299,721 shares of common stock held by VHCP II Co. Read SEC document |
| May 27, 2020 Filed May 28, 2020 18:34 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock | 125,162 | $7.23 | $904,921.26 |
DisclosureSEC source: 0001738048-20-000002 · edgar.xml · nonDerivative · entry 3 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 2,521,526 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.63 to $7.62, inclusive. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Dr. Koh, Mr. Shah, VHCPM III and VHCPM II disclaim beneficial ownership over all shares held by VHCP III, VHCP III Co, VHCP II and VHCP II Co, except to the extent of their respective indirect pecuniary interests therein. F7 · ownership.nature: Represents (a) 1,441,054 shares of common stock held by VHCP III, (b) 143,978 shares of common stock held by VHCP III Co, (c) 666,439 shares of common stock held by VHCP II, and (d) 270,055 shares of common stock held by VHCP II Co. Read SEC document |
| May 26, 2020 Filed May 28, 2020 18:34 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock | 390,547 | $9.78 | $3,819,549.66 |
DisclosureSEC source: 0001738048-20-000002 · edgar.xml · nonDerivative · entry 2 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 2,396,364 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.40 to $10.00, inclusive. F3 · ownership.nature: VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Dr. Koh, Mr. Shah, VHCPM III and VHCPM II disclaim beneficial ownership over all shares held by VHCP III, VHCP III Co, VHCP II and VHCP II Co, except to the extent of their respective indirect pecuniary interests therein. F5 · ownership.nature: Represents (a) 1,369,523 shares of common stock held by VHCP III, (b) 136,832 shares of common stock held by VHCP III Co, (c) 633,359 shares of common stock held by VHCP II, and (d) 256,650 shares of common stock held by VHCP II Co. Read SEC document |
| May 26, 2020 Filed May 28, 2020 18:34 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock | 309,453 | $8.79 | $2,720,091.87 |
DisclosureSEC source: 0001738048-20-000002 · edgar.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 2,005,817 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.40 to $9.39, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (4), (6), (8), (10) and (12) to this Form 4. F2 · ownership.nature: Represents (a) 1,146,325 shares of common stock held by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (b) 114,532 shares of common stock held by VHCP Co-Investment Holdings III, LLC ("VHCP III Co"), (c) 530,137 shares of common stock held by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), and (d) 214,823 shares of common stock held by VHCP Co-Investment Holdings II, LLC ("VHCP II Co"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Dr. Koh, Mr. Shah, VHCPM III and VHCPM II disclaim beneficial ownership over all shares held by VHCP III, VHCP III Co, VHCP II and VHCP II Co, except to the extent of their respective indirect pecuniary interests therein. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 17:56 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | PurchaseCommon Stock | 400,000 | $34.50 | $13,800,000.00 |
DisclosureSEC source: 0001738048-19-000002 · edgar.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 4,016,873 F1 · shares: Consists of an aggregate of 363,640 shares of Common Stock purchased by Venrock Healthcare Capital Partners III, L.P. ("VHCP III") and 36,360 shares of Common Stock purchased by VHCP Co-Investment Holdings III, LLC ("Co-Invest III") (collectively, the "VHCP III Funds"). F2 · balance_after: Consists of an aggregate of 2,287,598 shares of Common Stock held by VHCP III, 228,644 shares of Common Stock held by Co-Invest III, 1,067,801 shares of Common Stock held by Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and 432,830 shares of Common Stock held by VHCP Co-Investment Holdings II, LLC ("Co-Invest II" and collectively with VHCP II and the VHCP III Funds, the "VHCP Funds"). F3 · ownership.nature: VHCP Management III, LLC ("VHCPM III") is the sole general partner and the sole manager of VHCP III and Co-Invest III, respectively, and may be deemed to own the shares held by VHCP III and Co-Invest III. VHCP Management II, LLC ("VHCPM II") is the sole general partner and the sole manager of VHCP II and Co-Invest II, respectively, and may be deemed to own the shares held by VHCP II and Co-Invest II. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Drs. Koh and Shah, VHCPM II and VHCPM III disclaim beneficial ownership over all shares held by the VHCP Funds except to the extent of their indirect proportionate pecuniary interest therein. Read SEC document |
| October 28, 2019 Filed Oct 28, 2019 17:15 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 333,010 | $0.44 | $146,091.49 |
DisclosureSEC source: 0001209191-19-054264 · doc4.xml · nonDerivative · entry 3 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,435,173 F1 · date: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F6 · shares: Consists of: 149,726 shares sold by Venrock Healthcare Capital Partners II, LP, 60,700 shares sold by VHCP Co-Investment Holdings II, LLC, 111,441 shares sold by Venrock Healthcare Capital Partners III, LP and 11,143 shares sold by VHCP Co-Investment Holdings III, LLC. F3 · price: The price in Column 4 is a weighted average price. These shares were sold in multiple transactions a prices within a range of $1.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. F4 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 17:15 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 56,242 | $0.45 | $25,511.37 |
DisclosureSEC source: 0001209191-19-054264 · doc4.xml · nonDerivative · entry 2 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,768,183 F1 · date: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F5 · shares: Consists of: 25,287 shares sold by Venrock Healthcare Capital Partners II, LP, 10,252 shares sold by VHCP Co-Investment Holdings II, LLC, 18,821 shares sold by Venrock Healthcare Capital Partners III, LP and 1,882 shares sold by VHCP Co-Investment Holdings III, LLC. F3 · price: The price in Column 4 is a weighted average price. These shares were sold in multiple transactions a prices within a range of $1.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. F4 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 17:15 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 704,595 | $0.50 | $353,354.39 |
DisclosureSEC source: 0001209191-19-054264 · doc4.xml · nonDerivative · entry 1 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,824,425 F1 · date: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F2 · shares: Consists of: 316,797 shares sold by Venrock Healthcare Capital Partners II, LP, 128,431 shares sold by VHCP Co-Investment Holdings II, LLC, 235,791 shares sold by Venrock Healthcare Capital Partners III, LP and 23,576 shares sold by VHCP Co-Investment Holdings III, LLC. F3 · price: The price in Column 4 is a weighted average price. These shares were sold in multiple transactions a prices within a range of $1.00. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. F4 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 16:08 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | SaleCommon Stock | 500,000 | $28.75 | $14,375,000.00 |
DisclosureSEC source: 0001602264-19-000001 · edgar.xml · nonDerivative · entry 1 Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Venrock Healthcare Capital Partners III, L.P. · CIK 0001738048 · 10% owner VHCP Co-Investment Holdings III, LLC · CIK 0001750761 · 10% owner VHCP Management III, LLC · CIK 0001738053 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 1,544,112 F1 · balance_after: Consists of (i) 408,110 shares held by Venrock Healthcare Capital Partners II, L.P. ("VHCP2"), (ii) 165,372 shares held by VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"), (iii) 882,461 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3") and (iv) 88,169 shares held by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3"). F2 · ownership.nature: VHCP Management II, LLC ("VHCPM2") is the general partner of VHCP2 and the manager of VHCP Co-2 and may be deemed to beneficially own these shares. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM2, VHCPM3, Bong Koh and Nimish Shah expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,016,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-19-003374 · dp103684_4-venrock.xml · derivative · entry 4 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Common Stock · 1,016,492 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F3 · shares: Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F1 · derivative.exercise_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F1 · derivative.expiration_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F3 · derivative.underlying_shares: Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F4 · ownership.nature: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,105,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-19-003374 · dp103684_4-venrock.xml · derivative · entry 3 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Common Stock · 1,105,529 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F2 · shares: Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F1 · derivative.exercise_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F1 · derivative.expiration_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F2 · derivative.underlying_shares: Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC. F4 · ownership.nature: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | ConversionCommon Stock | 1,016,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-19-003374 · dp103684_4-venrock.xml · nonDerivative · entry 2 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 2,122,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F4 · ownership.nature: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 20:31 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | ConversionCommon Stock | 1,105,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950103-19-003374 · dp103684_4-venrock.xml · nonDerivative · entry 1 Venrock Associates VII, L.P. · CIK 0001614766 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner Venrock Partners VII, L.P. · CIK 0001614765 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Venrock Management VII, LLC · CIK 0001614686 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 1,105,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date. F4 · ownership.nature: Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein. Read SEC document |
| January 23, 2019 Filed Mar 14, 2019 17:51 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 142,857 | $0.70 | $99,999.90 |
DisclosureSEC source: 0001209191-19-019526 · doc4.xml · nonDerivative · entry 1 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 7,529,020 F1 · date: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F2 · ownership.nature: Consists of (i) 129,871 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 12,986 shares purchased by VHCP Co-Investment Holdings III, LLC. F3 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co- Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| September 17, 2018 Filed Sep 17, 2018 16:42 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 60,000 | $1.18 | $70,944.00 |
DisclosureSEC source: 0001209191-18-051215 · doc4.xml · nonDerivative · entry 3 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 7,386,163 F3 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co- Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. F4 · ownership.nature: Consists of (i) 54,546 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 5,454 shares purchased by VHCP Co-Investment Holdings III, LLC. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 16:42 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 75,000 | $1.23 | $92,250.00 |
DisclosureSEC source: 0001209191-18-051215 · doc4.xml · nonDerivative · entry 2 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 7,326,163 F2 · ownership.nature: Consists of (i) 68,183 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 6,817 shares purchased by VHCP Co-Investment Holdings III, LLC. F3 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co- Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 16:42 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 75,000 | $1.19 | $89,160.00 |
DisclosureSEC source: 0001209191-18-051215 · doc4.xml · nonDerivative · entry 1 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 7,251,163 F1 · date: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F2 · ownership.nature: Consists of (i) 68,183 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 6,817 shares purchased by VHCP Co-Investment Holdings III, LLC. F3 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co- Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| September 12, 2018 Filed Sep 12, 2018 21:00 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 75,000 | $1.15 | $85,912.50 |
DisclosureSEC source: 0001209191-18-050736 · doc4.xml · nonDerivative · entry 3 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 7,176,163 F4 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. F6 · ownership.nature: Consists of (i) 68,183 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 6,817 shares purchased by VHCP Co-Investment Holdings III, LLC. Read SEC document |
| September 11, 2018 Filed Sep 12, 2018 21:00 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 200,000 | $1.14 | $228,840.00 |
DisclosureSEC source: 0001209191-18-050736 · doc4.xml · nonDerivative · entry 2 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 7,101,163 F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10894 to $1.1990, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F3 · ownership.nature: Consists of (i) 181,820 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 18,180 shares purchased by VHCP Co-Investment Holdings III, LLC. F4 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:00 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 200,000 | $1.22 | $243,640.00 |
DisclosureSEC source: 0001209191-18-050736 · doc4.xml · nonDerivative · entry 1 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,901,163 F1 · date: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.2099 to $1.2265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F3 · ownership.nature: Consists of (i) 181,820 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 18,180 shares purchased by VHCP Co-Investment Holdings III, LLC. F4 · ownership.nature: Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| September 07, 2018 Filed Sep 7, 2018 17:45 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 60,000 | $0.90 | $53,742.00 |
DisclosureSEC source: 0001209191-18-050122 · doc4.xml · nonDerivative · entry 3 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,701,163 F3 · ownership.nature: Consists of (i) 54,546 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 5,454 shares purchased by VHCP Co-Investment Holdings III, LLC. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 17:45 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 50,000 | $0.84 | $42,095.00 |
DisclosureSEC source: 0001209191-18-050122 · doc4.xml · nonDerivative · entry 2 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,641,163 F2 · ownership.nature: Consists of (i) 45,455 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 4,545 shares purchased by VHCP Co-Investment Holdings III, LLC. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 17:45 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 50,000 | $0.85 | $42,325.00 |
DisclosureSEC source: 0001209191-18-050122 · doc4.xml · nonDerivative · entry 1 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,591,163 F1 · date: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F2 · ownership.nature: Consists of (i) 45,455 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 4,545 shares purchased by VHCP Co-Investment Holdings III, LLC. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 19:31 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 66,393 | $0.65 | $43,108.97 |
DisclosureSEC source: 0001209191-18-047212 · doc4.xml · nonDerivative · entry 3 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,541,163 F4 · ownership.direct: Consists of (i) 60,358 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 6,035 shares purchased by VHCP Co-Investment Holdings II, LLC. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 19:31 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 272,000 | $0.65 | $175,902.40 |
DisclosureSEC source: 0001209191-18-047212 · doc4.xml · nonDerivative · entry 2 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,474,770 F3 · ownership.direct: Consists of (i) 247,275 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 24,725 shares purchased by VHCP Co-Investment Holdings III, LLC. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 19:31 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 190,977 | $0.65 | $123,867.68 |
DisclosureSEC source: 0001209191-18-047212 · doc4.xml · nonDerivative · entry 1 VENROCK ASSOCIATES IV L P · CIK 0001277997 · 10% owner Venrock Partners, L.P. · CIK 0001305239 · 10% owner Venrock Partners Management, LLC · CIK 0001305240 · 10% owner Venrock Management IV, LLC · CIK 0001305238 · 10% owner VENROCK ENTREPRENEURS FUND IV L P · CIK 0001277994 · 10% owner VEF Management IV, LLC · CIK 0001305243 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 6,202,770 F1 · date: This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co-Investment Holdings II, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons. F2 · ownership.direct: Consists of (i) 173,617 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 17,360 shares purchased by VHCP Co-Investment Holdings III, LLC. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:33 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,905 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-030122 · doc4.xml · derivative · entry 5 Koh Bong Y · CIK 0001615979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,905 shares Expires 2028-03-13 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:33 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,454 | $0.00 Strike: $69.25 | $0.00 |
DisclosureSEC source: 0001209191-18-030122 · doc4.xml · derivative · entry 4 Koh Bong Y · CIK 0001615979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,454 shares Expires 2027-05-30 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:33 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,496 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030122 · doc4.xml · derivative · entry 3 Koh Bong Y · CIK 0001615979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,496 shares Expires 2026-02-10 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:33 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerCommon Stock | 1,035,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030122 · doc4.xml · nonDerivative · entry 2 Koh Bong Y · CIK 0001615979 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F1 · price: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · ownership.nature: The Reporting Person, a member of the Board of Directors of the Issuer, is a member of VHCP Management II, LLC, the sole general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCPII") and the sole manager of VHCP Co-Investment Holdings II, LLC ("Co-Invest II") and, as such, may be deemed to beneficially own the securities owned by each of VHCPII and Co-Invest II. The Reporting Person disclaims beneficial ownership of the shares beneficially owned by VHCPII and Co-Invest II, except to the extent of his pecuniary interest therein. F4 · ownership.nature: Consists of (i) 736,871 shares held by VHCPII, and (ii) 298,786 shares held by Co-Invest II. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:33 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerCommon Stock | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030122 · doc4.xml · nonDerivative · entry 1 Koh Bong Y · CIK 0001615979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2 · shares: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. Read SEC document |
| March 13, 2018 Filed Mar 30, 2018 18:07 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantStock Option (Right to Buy) · Derivative | 2,905 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-022245 · doc4.xml · derivative · entry 3 Koh Bong Y · CIK 0001615979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,905 Underlying: Common Stock · 2,905 shares Expires 2028-03-13 F4 · derivative.exercise_date: This option shall vest and become exercisable on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. Read SEC document |
| March 13, 2018 Filed Mar 30, 2018 18:07 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantCommon Stock | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-022245 · doc4.xml · nonDerivative · entry 1 Koh Bong Y · CIK 0001615979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. F1 · price: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 21:09 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 41,331 | $0.53 | $21,905.43 |
DisclosureSEC source: 0001458177-18-000001 · edgar.xml · nonDerivative · entry 2 VENROCK HEALTHCARE CAPITAL PARTNERS LP · CIK 0001458177 · 10% owner VHCP Co-Investment Holdings, LLC · CIK 0001479354 · 10% owner VHCP Management, LLC · CIK 0001479355 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 F3 · ownership.nature: VHCP Management, LLC ("VHCP Management") is the general partner of VHCP and the manager of Co-Invest and may be deemed to beneficially own these shares. VHCP Management II, LLC ("VHCP Management II") is the general partner of VHCP II and the manager of Co-Invest II and may be deemed to beneficially own these shares. Drs. Bong Koh and Nimish Shah are the managing members of VHCP Management and VHCP Management II and may be deemed to beneficially own these shares. Drs. Koh and Shah, VHCP Management and VHCP Management II expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 21:09 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 1,500,000 | $0.55 | $825,000.00 |
DisclosureSEC source: 0001458177-18-000001 · edgar.xml · nonDerivative · entry 1 VENROCK HEALTHCARE CAPITAL PARTNERS LP · CIK 0001458177 · 10% owner VHCP Co-Investment Holdings, LLC · CIK 0001479354 · 10% owner VHCP Management, LLC · CIK 0001479355 · 10% owner Venrock Healthcare Capital Partners II, L.P. · CIK 0001602264 · 10% owner VHCP Co-Investment Holdings II, LLC · CIK 0001615983 · 10% owner VHCP Management II, LLC · CIK 0001602263 · 10% owner Koh Bong Y · CIK 0001615979 · 10% owner Shah Nimish P · CIK 0001698082 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 41,331 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.50 to $0.63, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Consists of: 10,482 shares held directly by Venrock Healthcare Capital Partners, L.P. ("VHCP"); 20,585 shares held directly by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"); 1,917 shares held directly by VHCP Co-Investment Holdings, LLC ("Co-Invest"); and 8,347 shares held directly by VHCP Co-Investment Holdings II, LLC ("Co-Invest II"). F3 · ownership.nature: VHCP Management, LLC ("VHCP Management") is the general partner of VHCP and the manager of Co-Invest and may be deemed to beneficially own these shares. VHCP Management II, LLC ("VHCP Management II") is the general partner of VHCP II and the manager of Co-Invest II and may be deemed to beneficially own these shares. Drs. Bong Koh and Nimish Shah are the managing members of VHCP Management and VHCP Management II and may be deemed to beneficially own these shares. Drs. Koh and Shah, VHCP Management and VHCP Management II expressly disclaim beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 18:06 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantStock Option (Right to Buy) · Derivative | 2,454 | $0.00 Strike: $69.25 | $0.00 |
DisclosureSEC source: 0001209191-17-036894 · doc4.xml · derivative · entry 1 Koh Bong Y · CIK 0001615979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454 Underlying: Common Stock · 2,454 shares Expires 2027-05-30 F1 · derivative.exercise_date: The option shall vest and become exercisable (i) in twelve equal monthly installments beginning on June 30, 2017, or (ii) on the date of the Issuer's next annual stockholder meeting, whichever comes first, in each case subject to the Reporting Person's Continuous Service (as that term is defined in the Issuer's 2016 Equity Incentive Plan) through each such date. F2 · ownership.direct: The Reporting Person is a member of VR Management, LLC ("Management Company"). Under an agreement between the Reporting Person and the Management Company, the Reporting Person is deemed to hold the reported shares for the sole benefit of the Management Company and must exercise the reported shares solely upon the direction of the Management Company, which is entitled to the shares. The Management Company may be deemed the indirect beneficial owner of the reported shares, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.